论文部分内容阅读
目的观察小剂量地西他滨治疗骨髓增生异常综合征的临床效果。方法选择2014年1月-2016年12月骨髓增生异常综合征患者30例,均给予地西他滨10~20 mg·m-2·d-1静脉输注3 h,连续应用5 d,28 d为1个周期,观察其治疗效果及不良反应。结果治疗效果:完全缓解3例(10.00%),部分缓解14例(46.67%)、未缓解13例(43.33%),总缓解率为56.67%。不良反应:骨髓抑制(白细胞减少)2例(6.67%),恶心6例(20.00%),发热2例(6.67%),肝功能异常3例(10.00%),不良反应总发生率为43.33%,所有不良反应在停药或降低药量后有所减少,未并发严重感染、脏器功能衰竭等严重不良反应。结论小剂量地西他滨治疗骨髓增生异常综合征完全缓解及部分缓解率高,药物不良反应发生率低。
Objective To observe the clinical efficacy of low-dose decitabine in the treatment of myelodysplastic syndromes. Methods Thirty patients with myelodysplastic syndromes from January 2014 to December 2016 were given intravenous infusion of decitabine 10 ~ 20 mg · m-2 · d-1 for 3 hours, and were continuously administered for 5 days, 28 days d for a cycle, observe the treatment effect and adverse reactions. Results The therapeutic effects were complete remission in 3 cases (10.00%), partial remission in 14 cases (46.67%), unresponsiveness in 13 cases (43.33%) and total remission rate of 56.67%. Adverse reactions: Myelosuppression (leukopenia) in 2 cases (6.67%), nausea in 6 cases (20.00%), fever in 2 cases (6.67%), liver dysfunction in 3 cases (10.00%), the total incidence of adverse reactions was 43.33% , All adverse reactions in the withdrawal or reduce the dose decreased, no serious complications of infection, organ failure and other serious adverse reactions. Conclusion Low-dose decitabine treatment of myelodysplastic syndromes complete remission and partial remission rate, the incidence of adverse drug reactions is low.